tiprankstipranks
Trending News
More News >

Radiopharm Theranostics Advances in Clinical Trials and Secures Major Investment

Story Highlights
  • Radiopharm Theranostics secures US$5 million from Lantheus to advance its clinical pipeline.
  • Radiopharm’s RAD 101 and RAD202 show promising results in cancer detection and treatment.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Radiopharm Theranostics Advances in Clinical Trials and Secures Major Investment

Confident Investing Starts Here:

An announcement from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.

Radiopharm Theranostics Limited announced significant advancements in its clinical trials and shareholder structure. Lantheus Holdings Inc. increased its stake to 12.16% through a US$5 million placement, providing funds to advance Radiopharm’s clinical pipeline. The company reported successful detection of brain metastases using RAD 101, a novel imaging agent, and positive preclinical data for RAD202, a HER2-targeting radiopharmaceutical. These developments underscore Radiopharm’s potential to improve cancer diagnostics and treatment, positioning it as a key player in the radiopharmaceutical industry.

More about Radiopharm Theranostics Limited

Radiopharm Theranostics Limited is a developer of radiopharmaceutical products, focusing on diagnostic and therapeutic uses. The company is engaged in advancing a clinical pipeline that includes trials for solid tumor cancers such as brain, lung, breast, and pancreas, leveraging its expertise in radiopharmaceuticals to enhance cancer detection and treatment.

YTD Price Performance: 5.00%

Average Trading Volume: 7,260,583

Technical Sentiment Signal: Buy

Current Market Cap: A$49.01M

See more insights into RAD stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1